Sterile CAR-T cell lines for faster leukaemia research

Amsbio is helping researchers fast-track CAR-T cell therapy development with a growing portfolio of experimental cell lines, recombinant proteins, and screening services.

CAR-T therapy reached a key milestone in 2017 when the FDA approved its use for children and adolescents with B cell acute lymphoblastic leukaemia (ALL). Since then, research has expanded to explore CAR-T cells targeting multiple B cell proteins, improving anti-tumour activity, reducing relapse caused by antigen escape, and tackling tumour heterogeneity.

“Amsbio’s ready-to-use CAR-T cell lines are designed to support this cutting-edge research,” said Dr Maja Petkovic, Business Development Manager. “Our portfolio includes knockout lines for TCR, B2M, and CIITA, allowing scientists to model universal CAR-T cells. We also provide sterile, pathogen- and mycoplasma-free lines expressing key CAR targets such as BCMA, CD19, CD20, and CD22, many equipped with luciferase reporters for easy monitoring.”

Dr Petkovic added: “Researchers can now access CAR-expressing cells ready for assay design, optimisation, and use as positive controls in co-culture experiments. We also offer bispecific CAR-T cells targeting CD19 & CD22, supporting the development of next-generation therapies.”

For further details on ready-to-use sterile cell lines for CAR-T therapy research please contact Amsbio.

More information online